Involvement of the gastrointestinal (GI) tract occurs in up to 90% of patients with systemic sclerosis (SSc) 1, 2 . We have demonstrated that GI symptoms are associated with healthrelated quality of life (HRQOL) 3, 4 in SSc and also with pain 5 , depression 6 , fatigue 7 , pruritus 8 , and malnutrition 9 . Although severe GI involvement affects only 8% of patients with SSc, mortality can be high in that situation, with only 15% of such patients alive after 9 years 10 .
Because GI involvement is so prevalent and important in SSc, it is important to have a well validated, reliable measure of GI tract disease for the purposes of future research. The University of California at Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (UCLA SCTC GITI) has recently been developed to serve this purpose 11 . We wished to confirm the internal consistency and validity of this instrument in a different population from the American one in which it was first tested 11 . We thus administered the questionnaire to a sample of patients from the Canadian Scleroderma Research Group patient registry.
MATERIALS AND METHODS
Study subjects. Our study subjects were recruited from those enrolled in the Canadian Scleroderma Research Group Registry. Patients in this registry are recruited from 15 centers across Canada. They must have a diagnosis of SSc made by the referring rheumatologist, be > 18 years of age, and be fluent in either English or French. Patients are seen yearly. The patients included in our study were a convenience sample of 113 consecutive English-speaking patients from 1 site only who agreed to fill out 1 extra questionnaire. All patients recruited into the registry undergo an extensive medical evaluation with standardized reporting of history, physical evaluation, and laboratory investigations.
Instrument. We were given the UCLA SCTC GITI version 2.0 by its author 11, 12 . The English version is also available free of charge at http://uclascleroderma.researchcore.org/. This is a self-administered questionnaire with a total of 34 questions that form 7 scales: reflux, distension/bloating, fecal soilage, diarrhea, social functioning, emotional well-being, and constipation. The items are scored on a 0 to 3 possible range, where 0 indicates better health and 3 indicates worse health, except for questions 15 and 31, which ask, "In the past 1 week, have you noticed your stools becoming... (15) watery (yes/no) and (31) harder (yes/no)". These questions are scored on 0 (better health) and 1 (worse health) possible range. Each scale is scored 0-3 except for diarrhea (0-2) and constipation (0-2.5) and there is an overall score of 0-3 as well. The reliability and validity of this instrument have been reported in the initial population 11 .
Other variables. Disease duration is calculated from the first non-Raynaud's phenomenon manifestation, as in other studies 12, 13, 14, 15, 16, 17 . As part of the routine questions for the CSRG, to assess GI involvement patients answer yes/no to a series of 14 questions concerning appetite loss, difficulty swallowing, regurgitation of acid, nocturnal choking, heartburn, early satiety, abdominal bloating, nausea and vomiting, constipation, diarrhea, need for antibiotics for diarrhea, greasy stools, fecal incontinence, and the need for parenteral nutrition. We reviewed protocols from 7 major SSc centers in North America and compiled this list of the GI symptoms included in those protocols. The overall GI involvement is assessed as the total number of questions to which the patient answers "yes." In other studies we have demonstrated an association between this score and quality of life 3 and we have shown that it has an excellent association with measures of malnutrition 9 , and these studies thus validate this measure. In addition, we used combinations of physician-defined and patient-defined answers on the case report forms to determine what we will refer to as 7 "clinical GI tract diagnoses." Detailed definitions of gastroesophageal reflux disease (GERD), gastroparesis, bacterial overgrowth, pseudo-obstruction, diarrhea, rectal incontinence, and constipation are available as accessory material online.
Statistics.
As closely as possible, we tried to reproduce the methodology of the authors of the UCLA SCTC GITI in their initial study of validation 11 . Internal consistency as a measure of reliability was estimated using Cronbach's alpha coefficient. Correlations ≤ 0.29 were considered to be small, between 0.30 and 0.49 moderate, and ≥ 0.50 large.
We examined the ability of the UCLA SCTC GITI 2.0 to differentiate among patients with mild, mild-moderate, and severe GI tract involvement. In the validation of Khanna, et al 11 , patients were given a question to globally assess GI involvement: "How severe have your digestive tract symptoms been in general during the last 7 days?" (very mild, mild, moderate, severe, very severe). Instead of this question we used the GI question from the SSc version of the Health Assessment Questionnaire (HAQ; GI-S-HAQ) 18 , which was originally a 150-mm visual analog scale. We adapted that to an 11-point numerical rating scale with the same anchors. For purposes of developing categories of GI severity, this was collapsed into 3 groups. Because of extremely right-skewed results, the categories we created were normal (score = 0), mild-moderate severity (scores = 1-3), and severe (scores = 4-10). The Tukey-Kramer posthoc adjustment was used to test for any significant differences in the analyses of variance.
We also hypothesized that symptom-specific scale scores (e.g., the reflux scale) would be higher (worse) in patients with a specific clinical GI tract diagnosis (e.g., GERD).
Exploratory factor analysis was performed to evaluate the underlying structure of the 7 multi-item scales 19 . Criteria used to select the most plausible model included components accounting for ≥ 5% of the variance and principal component eigenvalues > 1 20 . Oblique promax rotation was performed to estimate factor correlations (rather than assume they were uncorrelated) 21 .
All statistical analyses were performed with R 2.10.0 22 ; p values < 0.05 were considered statistically significant.
RESULTS
All 113 patients given a questionnaire returned the completed questionnaire. Table 1 shows the characteristics of the patients.
There were several differences between our sample and that of Khanna, et al 11 . Our subjects were slightly older, only 5.3% had a postgraduate degree versus 20.4% of the UCLA cohort, 62.2% of our subjects had limited disease versus 40.7%, and self-rated GI severity tended to be lower in our cohort (54.9% with no symptoms vs 19.1%). This sample of 113 subjects seemed to have less GI involvement than our entire cohort of 1160 patients. Figure 1 shows the good relationship between the UCLA SCTC GITI overall score and the GI-S-HAQ (A) and the total number of GI symptoms (B). Figure 1C shows that the relationship is slightly better when the psychosocial aspects of the UCLA SCTC GITI are removed. Internal consistency. Table 2 demonstrates good internal consistency of items from the UCLA SCTC GITI. There was a moderately high percentage with a ceiling effect, which is slightly more than the same data from the original cohort. Validity. Table 3 shows the relationship between the scales of the UCLA SCTC GITI score and the GI-S-HAQ question. The correlations were all highly significant, with both each subscale and the overall score. There were also good correlations between the number of GI symptoms and both the total UCLA SCTC GITI score (r = 0.77, p < 0.001) and the total UCLA SCTC GITI score with the psychosocial scales "social functioning" and "emotional well-being" omitted (r = 0.79, p < 0.001). Table 4 shows the ability of the UCLA SCTC GITI to differentiate between the categorical groupings of the GI-S-HAQ. In most cases the UCLA SCTC GITI was able to differentiate well between the patients with no symptoms and either mild-moderate or severe symptoms. Differentiation between mild-moderate and severe categories was not good due to the reduced number of patients in the severe category and the large range of values included in this category. This was true for all scales and the overall score. Table 5 shows the relationship between clinical GI tract diagnoses in our sample and the corresponding scales of the UCLA SCTC GITI. The scales of the UCLA SCTC GITI that we chose to correspond with the GI diagnoses were reflux for GERD; distension/bloating for gastroparesis; distension/ bloating for bacterial overgrowth; distension/bloating for pseudo-obstruction; diarrhea for diarrhea; fecal soilage for rectal incontinence; constipation for constipation. In each case, except for pseudo-obstruction, the UCLA SCTC GITI scale scores differentiated well those patients with clinical involvement of the corresponding GI problem from those without.
Multiple linear regression was performed to assess the contribution of the UCLA SCTC GITI to HRQOL as measured by the Medical Outcomes Study Short-Form 36 (SF-36) questionnaire (Table 6 ). Covariates included age, disease duration, sex, and race. The UCLA SCTC GITI had a statistically significant association with both the SF-36 physical component summary (PCS) and the mental component summary (MCS) after adjustment for possible confounding variables. A 1 SD increase in UCLA SCTC GITI (0.43) is associated with a decrease of 3.14 (95% CI 1.06, 5.22) in the PCS and 2.98 in the MCS (95% CI 1.04, 4.92). The models explain 6% of the variance of the SF-36 MCS and 4.6% of the variance of the SF-36 PCS.
DISCUSSION
We assessed internal consistency and construct validity of the UCLA SCTC GITI in a sample of 113 Canadian patients. We demonstrated good internal consistency. Construct validity was also good in that the overall score of the instrument correlated well with the GI scale of the S-HAQ and the total num- ber of GI symptoms that patients complained of. Each subscale also correlated well with the GI-S-HAQ and both all scales and the overall score were able to differentiate between the categorical groupings of the GI-S-HAQ. The UCLA SCTC GITI scale scores also differentiated well those patients with clinical involvement of the GI problem corresponding to that scale from those without, except for pseudo-obstruction. Factor analysis showed that the primary factor is dominated by diarrhea (and related symptoms) and the secondary factor is dominated by constipation (and related symptoms). These results are similar to those of Khanna, et al 11 . In addition, the data show clear evidence that GI involvement affects HRQOL as measured in our study by the SF-36. Our patients differed somewhat from those in the original validation study. In particular, our patients had less severe GI disease. In addition, our subjects were slightly older, fewer had a postgraduate degree, and more had limited disease. As there is some suggestion that the validity of an instrument is population-specific 23, 24 , we feel that our study is important in that it confirms the validity of the UCLA SCTC GITI in a substantially different population of patients from those in the initial report. This validation exercise thus implies that the instrument is likely to be valid in a more diverse group than those in the original study group.
Our study confirms that the UCLA SCTC GITI version 2.0 will be a useful tool for assessing the role of GI involvement in SSc. One recent report has already used the tool to demonstrate that GI tract involvement is associated with depression 25 . To our knowledge this is the only such tool that has been developed specifically for use in SSc. Baron 
